The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field Inflammatix receives an ...
Unlike conventional diagnostics that focus solely on identifying pathogens, TriVerity delivers three integrated host-response scores—bacterial infection, viral infection, and illness severity—from a ...
SUNNYVALE, Calif., June 10, 2025 /PRNewswire/ -- Inflammatix, a leader in AI-powered immune response diagnostics, today announced the appointment of Martín Vazquez as chief operating officer (COO).
SUNNYVALE, Calif., Jan. 21, 2025 /PRNewswire/ -- Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing ...
SUNNYVALE, Calif., Nov. 11, 2024 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today announced initiation of the TriVerity™ for Improved Management of Emergency Department ...
Just a few weeks later than expected, Inflammatix Inc. secured U.S. FDA clearance of the Triverity test system for use in emergency triage of patients with suspected acute infection or sepsis. The ...
First Interventional Study Designed to Demonstrate the Clinical Utility of the TriVerity Test and its Impact on Patient Management "As the first interventional study to demonstrate the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results